AZN
Price
$156.91
Change
-$0.79 (-0.50%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
256.26B
28 days until earnings call
Intraday BUY SELL Signals
BIIB
Price
$220.01
Change
-$2.81 (-1.26%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
33.79B
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AZN vs BIIB

AZN vs BIIB Comparison Chart in %
View a ticker or compare two or three
VS
AZN vs. BIIB commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Hold and BIIB is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
AZN vs BIIB: Fundamental Ratings
AZN
BIIB
OUTLOOK RATING
1..100
1815
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
21100
SMR RATING
1..100
4484
PRICE GROWTH RATING
1..100
4433
P/E GROWTH RATING
1..100
525
SEASONALITY SCORE
1..100
350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZN's Valuation (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (78) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.

AZN's Profit vs Risk Rating (21) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.

AZN's SMR Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (84) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.

BIIB's Price Growth Rating (33) in the Biotechnology industry is in the same range as AZN (44) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to AZN’s over the last 12 months.

BIIB's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for AZN (52) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNBIIB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
53%
MACD
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
48%
Bullish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 8 days ago
57%
Bullish Trend 5 days ago
59%
Declines
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
51%
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
51%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (AZN: $157.70 vs. BIIB: $222.82)
Brand notoriety: AZN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 77% vs. BIIB: 185%
Market capitalization -- AZN: $256.26B vs. BIIB: $33.79B
AZN [@Pharmaceuticals: Major] is valued at $256.26B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $33.79B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.06T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $200.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 2 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).

  • AZN’s FA Score: 2 green, 3 red.
  • BIIB’s FA Score: 2 green, 3 red.
According to our system of comparison, AZN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 4 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).

  • AZN’s TA Score: 4 bullish, 5 bearish.
  • BIIB’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than AZN.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а -4.17% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -1.56% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -3.39%. For the same industry, the average monthly price growth was -8.55%, and the average quarterly price growth was +8.33%.

Reported Earning Dates

AZN is expected to report earnings on Oct 30, 2026.

BIIB is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-3.39% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
AZN
Daily Signal:
Gain/Loss:
BIIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CCHH1.000.10
+11.11%
CCH Holdings Ltd
TVACU10.65N/A
N/A
Texas Ventures Acquisition III Corp
MFC42.55-0.04
-0.09%
Manulife Financial Corp
PIPR65.78-0.19
-0.29%
Piper Sandler Companies
ENOV18.05-0.22
-1.20%
Enovis Corp

AZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZN
1D Price
Change %
AZN100%
-2.33%
BIIB - AZN
48%
Loosely correlated
-1.35%
LLY - AZN
44%
Loosely correlated
-0.62%
GILD - AZN
39%
Loosely correlated
-1.04%
MRK - AZN
28%
Poorly correlated
-1.03%
GSK - AZN
27%
Poorly correlated
-2.06%
More

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-1.35%
AMGN - BIIB
49%
Loosely correlated
-3.38%
AZN - BIIB
49%
Loosely correlated
-2.33%
PFE - BIIB
48%
Loosely correlated
-1.40%
MRK - BIIB
46%
Loosely correlated
-1.03%
ABBV - BIIB
41%
Loosely correlated
-0.63%
More